Abstract 1122‐000025: Gender in Dementia Patients with Lewy Body Dementia and Parkinson’s Disease with Dementia

2021 ◽  
Vol 1 (S1) ◽  
Author(s):  
Lidadi L Agbomi ◽  
Nneoma T Madubuike ◽  
Oreoluwa Coker‐Ayo ◽  
Chika P Onuoha ◽  
Samuel I Nathaniel ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Gender Differences ◽  
Parkinson's Disease ◽  
Lewy Body ◽  
African American Men ◽  
Lewy Body Dementia ◽  
Factors Associated ◽  
Dementia Patients ◽  
Parkinson’S Disease With Dementia ◽  
Demographic Risk

Introduction : Gender differences in dementia patients have been investigated extensively, however, demographic, risk, and pharmacological factors associated with gender differences in dementia patients associated with Lewy Body Dementia(LBD) and Parkinson’s disease with dementia (PDD) are not fully understood. We tested the hypothesis that specific factors may contribute to the observed gender differences in LBD and PDD patients. Methods : A 5‐year retrospective data analytical study was conducted using 4526 men and 3676 women collected from a regional hospital database. We performed logistic regression analysis to determine factors associated with gender differences in LBD and PDD patients. Multicollinearity and significant interactions between independent variables in the model were examined using variance inflation factors, while a Cox & Snell classification was applied to check the model fitness. Results : In the adjusted analysis, African‐American men (AAM) (OR = 0.249, 95% CI, 0.088‐0.703, P = 0.009) were more likely to present with PDD, while women with increasing age (OR = 1.042, 95% CI, 1.025‐1.058, P<0.002) were more likely to present with LBD. Escitalopram was associated with LBD in men (OR = 1.444, 95% CI, 1.079‐1.932, P = 0.014) and PDD in women (OR = 0.651, 95% CI, 0.468‐0.906, P = 0.011). Conclusions : Our findings revealed gender differences in LBD and PDD. More men presented with. PDD based on race, while women presented with LBD more based on age.

Lewy body dementia and Parkinson’s disease with dementia

2008 ◽  
Vol 255 (S5) ◽  
pp. 39-47 ◽  
Author(s):  
Richard Dodel ◽  
Ilona Csoti ◽  
Georg Ebersbach ◽  
Gerd Fuchs ◽  
Matthias Hahne ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Lewy Body ◽  
Lewy Body Dementia ◽  
Parkinson’S Disease With Dementia

Abstract 1122‐000042: Demographic and Pharmacological Characteristics of Dementia Patients with Parkinson’s Disease Stratified by Gender

2021 ◽  
Vol 1 (S1) ◽  
Author(s):  
Nneoma Madubuike ◽  
Lidadi L Agbomi ◽  
Chika P Onuoha ◽  
Oreoluwa Coker‐Ayo ◽  
Samuel Nathaniel ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Gender Differences ◽  
Parkinson's Disease ◽  
African American ◽  
Univariate Analysis ◽  
Women Patients ◽  
Men And Women ◽  
Factors Associated ◽  
Independent Variables ◽  
Dementia Patients

Introduction : Gender differences in dementia patients and Parkinson’s Disease have been investigated extensively; however, factors that contribute to gender differences in Parkinson’s Disease with Dementia patients (PDD) is not fully understood. In this study, we tested the hypothesis that specific, demographic, and pharmacological factors may be associated with men and women patients with PDD, and contribute to gender differences. Methods : Data collected for 5 years from 7594 PDD patients was analyzed using univariate analysis to determine different factors associated with men or women with PDD. Multicollinearity interactions between independent variables in the model were examined using variance inflation factors Results : Overall, 55.22% of the PDD patients were men while 44.77% were women. In the adjusted analysis, Aripiprazole (OR = 0.581, 95% CI, 0.302‐1.118, P = 0.104), ETOH (OR = 0.371, 95% CI, 0.260‐0.531, P<0.001) African American (0.249, 95% CI, 0.088‐0.703, P = 0.009) with PD were more likely to be men. The use of Aripiprazole (OR = 0.195, 95% CI, 0.06‐0.631, P = 0.006), Escitalopram (OR = 0.651, 95% CI, 0.468‐0.906, P = 0.011), and Tobacco (OR = 0.620, 95% CI, 0.444‐0.866, P = 0.005) were associated with women. Conclusions : This study showed that women presented fewer cases of PDD than men. The current study reveals gender differences in PDD patients associated with specific demographic and pharmacological factors

scholarly journals Cross-platform transcriptional profiling identifies common and distinct molecular pathologies in Lewy body diseases

2021 ◽  
Author(s):  
Rahel Feleke ◽  
Regina H. Reynolds ◽  
Amy M. Smith ◽  
Bension Tilley ◽  
Sarah A. Gagliano Taliun ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Neurodegenerative Diseases ◽  
Lewy Body ◽  
Molecular Mechanisms ◽  
Lewy Bodies ◽  
Subsequent Development ◽  
Lewy Body Dementia ◽  
Anterior Cingulate ◽  
Lewy Body Diseases

AbstractParkinson’s disease (PD), Parkinson’s disease with dementia (PDD) and dementia with Lewy bodies (DLB) are three clinically, genetically and neuropathologically overlapping neurodegenerative diseases collectively known as the Lewy body diseases (LBDs). A variety of molecular mechanisms have been implicated in PD pathogenesis, but the mechanisms underlying PDD and DLB remain largely unknown, a knowledge gap that presents an impediment to the discovery of disease-modifying therapies. Transcriptomic profiling can contribute to addressing this gap, but remains limited in the LBDs. Here, we applied paired bulk-tissue and single-nucleus RNA-sequencing to anterior cingulate cortex samples derived from 28 individuals, including healthy controls, PD, PDD and DLB cases (n = 7 per group), to transcriptomically profile the LBDs. Using this approach, we (i) found transcriptional alterations in multiple cell types across the LBDs; (ii) discovered evidence for widespread dysregulation of RNA splicing, particularly in PDD and DLB; (iii) identified potential splicing factors, with links to other dementia-related neurodegenerative diseases, coordinating this dysregulation; and (iv) identified transcriptomic commonalities and distinctions between the LBDs that inform understanding of the relationships between these three clinical disorders. Together, these findings have important implications for the design of RNA-targeted therapies for these diseases and highlight a potential molecular “window” of therapeutic opportunity between the initial onset of PD and subsequent development of Lewy body dementia.

scholarly journals Dementia with Parkinson's disease: Clinical diagnosis, neuropsychological aspects and treatment

2008 ◽  
Vol 2 (4) ◽  
pp. 261-266
Author(s):  
Jorge Lorenzo Otero
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Lewy Body ◽  
Task Force ◽  
Lewy Body Dementia ◽  
Data Bases ◽  
Main Text ◽  
Clinical Diagnoses ◽  
Movement Disorder Society ◽  
Selection Of

Abstract Dementia with Parkinson's disease represents a controversial issue in the complex group of alpha-synucleinopathies. The author acknowledges the concept of a "continuum" between Parkinson disease's (PD), Lewy body dementia (LBD), and dementia in Parkinson's disease (PDD). However, the practicing neurologist needs to identify the phenotypic signs of each dementia. The treatment and prognosis are different in spite of the overlaps between them. The main aim of this review was to characterize the clinical diagnoses of dementia associated with Parkinson's disease (PDD). Secondarily, the review discussed some epidemiological and neuropsychological issues. Selection of articles was not systematic and reflects the author's opinion, where the main text selected was the recommendations from the Movement Disorder Society Task Force for PDD diagnosis. The Pub Med, OVID, and Proquest data bases were used for the search.

scholarly journals Genetic modifiers of risk and age at onset in GBA associated Parkinson’s disease and Lewy body dementia

Brain ◽  
2019 ◽  
Vol 143 (1) ◽  
pp. 234-248 ◽  
Author(s):  
Cornelis Blauwendraat ◽  
Xylena Reed ◽  
Lynne Krohn ◽  
Karl Heilbron ◽  
Sara Bandres-Ciga ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Genetic Risk ◽  
Lewy Body ◽  
Disease Risk ◽  
Genetic Risk Score ◽  
Age At Onset ◽  
Lewy Body Dementia ◽  
Risk Variants ◽  
Genome Wide

Abstract Parkinson’s disease is a genetically complex disorder. Multiple genes have been shown to contribute to the risk of Parkinson’s disease, and currently 90 independent risk variants have been identified by genome-wide association studies. Thus far, a number of genes (including SNCA, LRRK2, and GBA) have been shown to contain variability across a spectrum of frequency and effect, from rare, highly penetrant variants to common risk alleles with small effect sizes. Variants in GBA, encoding the enzyme glucocerebrosidase, are associated with Lewy body diseases such as Parkinson’s disease and Lewy body dementia. These variants, which reduce or abolish enzymatic activity, confer a spectrum of disease risk, from 1.4- to &gt;10-fold. An outstanding question in the field is what other genetic factors that influence GBA-associated risk for disease, and whether these overlap with known Parkinson’s disease risk variants. Using multiple, large case-control datasets, totalling 217 165 individuals (22 757 Parkinson’s disease cases, 13 431 Parkinson’s disease proxy cases, 622 Lewy body dementia cases and 180 355 controls), we identified 1691 Parkinson’s disease cases, 81 Lewy body dementia cases, 711 proxy cases and 7624 controls with a GBA variant (p.E326K, p.T369M or p.N370S). We performed a genome-wide association study and analysed the most recent Parkinson’s disease-associated genetic risk score to detect genetic influences on GBA risk and age at onset. We attempted to replicate our findings in two independent datasets, including the personal genetics company 23andMe, Inc. and whole-genome sequencing data. Our analysis showed that the overall Parkinson’s disease genetic risk score modifies risk for disease and decreases age at onset in carriers of GBA variants. Notably, this effect was consistent across all tested GBA risk variants. Dissecting this signal demonstrated that variants in close proximity to SNCA and CTSB (encoding cathepsin B) are the most significant contributors. Risk variants in the CTSB locus were identified to decrease mRNA expression of CTSB. Additional analyses suggest a possible genetic interaction between GBA and CTSB and GBA p.N370S induced pluripotent cell-derived neurons were shown to have decreased cathepsin B expression compared to controls. These data provide a genetic basis for modification of GBA-associated Parkinson’s disease risk and age at onset, although the total contribution of common genetics variants is not large. We further demonstrate that common variability at genes implicated in lysosomal function exerts the largest effect on GBA associated risk for disease. Further, these results have implications for selection of GBA carriers for therapeutic interventions.

scholarly journals Nocturnal sleep enhances working memory training in Parkinson's disease but not Lewy body dementia

Brain ◽  
2012 ◽  
Vol 135 (9) ◽  
pp. 2789-2797 ◽  
Author(s):  
M. K. Scullin ◽  
L. M. Trotti ◽  
A. G. Wilson ◽  
S. A. Greer ◽  
D. L. Bliwise
Keyword(s):  
Parkinson’S Disease ◽  
Working Memory ◽  
Parkinson's Disease ◽  
Lewy Body ◽  
Lewy Body Dementia ◽  
Working Memory Training ◽  
Memory Training ◽  
Nocturnal Sleep
Sign in / Sign up

Export Citation Format

Share Document